Executive Director, Clinical Program Lead
Regeneron Pharmaceuticals, Inc.
Boston, MA, United States
Dr Vassili Valayannopoulos, M.D., Ph.D., MBA, is a Rare Metabolic Disease expert and an experienced pharmaceutical industry executive with more than 20 years’ experience in the Rare Genetic Disease space.
With training in pediatric metabolic medicine, clinical genetics and pediatric neurology and prior to joining the pharmaceutical industry, he served as Senior Faculty and Principal Investigator at the Department of Pediatric Inherited Metabolic Disorders and Pediatric Neurology at Necker-Enfants Malades University Hospital, Paris, France.
Dr Valayannopoulos conducted clinical research in collaboration with IMAGINE Research Center at Necker with a special focus on neurodegenerative metabolic diseases, gene therapy and lysosomal storage disorders, and worked with expert networks for inherited Metabolic disorders. He has served as Principal Investigator and national coordinator in several clinical trials for rare genetic diseases and is an author or coauthor on numerous peer-reviewed journal articles. He led for several years the Metabolic Training Course for clinicians and laboratory scientists sponsored by the Society for the Study of Inborn Errors of Metabolism.
Dr Valayannopoulos served in various Clinical Development and Medical Affairs leadership roles in the past 10 years. At Sanofi Genzyme he developed a portfolio of phase 4 and real-world studies focusing on lysosomal storage disorders; at Ultragenyx he led clinical development focusing on AAV-based gene therapy programs and more recently at Decibel Therapeutics and now at Regeneron he led the auditory sciences clinical programs and is now involved in Regeneron’s lysosomal storage disease programs.
Dr Valayannopoulos earned his medical degree and completed his pediatric residency program at Paul Sabatier University Medical School in Toulouse, France, and received university certification in Metabolic Medicine and Pediatric Neurology. He received his Master’s degree in Genetics of Development and Oncogenesis and his PhD in Molecular Biology, both from Paris Descartes University and his MBA from MIT Sloan School of Management.
Sunday, September 29, 2024
3:12 PM – 3:18 PM EDT
Disclosure information not submitted.